Suppr超能文献

洛氏综合征/登特2型疾病:对已知及新发现方面的全面综述

Lowe syndrome/Dent-2 disease: A comprehensive review of known and novel aspects.

作者信息

Recker Florian, Reutter Heiko, Ludwig Michael

机构信息

Department of Clinical Chemistry and Clinical Pharmacology, University of Bonn, Bonn, Germany.

Institute of Human Genetics, University of Bonn, Bonn, Germany; Department of Neonatology, Children's Hospital, University of Bonn, Bonn, Germany.

出版信息

J Pediatr Genet. 2013 Jun;2(2):53-68. doi: 10.3233/PGE-13049.

Abstract

The oculocerebrorenal syndrome of Lowe is a rare X-linked multisystemic disorder characterized by the triad of congenital cataracts, cognitive and behavioral impairment and a renal proximal tubulopathy in almost all of the patients. Whereas the ocular manifestations and severe hypotonia are present at birth, the renal involvement appears within the first months of life. Patients show progressive growth retardation and may develop a debilitating arthropathy. Treatment is symptomatic and life span rarely exceeds 40 yr. The causative OCRL gene, encodes an inositol polyphosphate 5-phosphatase. OCRL mutations were not only found in classic Lowe syndrome, but also in milder affected patients, classified as having Dent-2 disease. There is a phenotypic continuum within patients with Dent-2 disease and Lowe syndrome, suggesting that there are individual differences in the ability to compensate for loss of enzyme function. Researchers have conducted a large amount of work to understand the etiology responsible for the disease. However, the mechanisms leading to the clinical manifestations are still poorly understood and we are far from an effective therapy. In this review, we have included well-established findings and the most recent progress in understanding Lowe syndrome and Dent-2 disease.

摘要

洛氏眼脑肾综合征是一种罕见的X连锁多系统疾病,几乎所有患者都具有先天性白内障、认知和行为障碍以及近端肾小管病三联征。眼部表现和严重肌张力减退在出生时就存在,而肾脏受累则出现在生命的最初几个月。患者表现出进行性生长发育迟缓,并可能发展为使人衰弱的关节病。治疗以对症治疗为主,寿命很少超过40岁。致病基因OCRL编码一种肌醇多磷酸5-磷酸酶。OCRL突变不仅在典型的洛氏综合征患者中发现,在病情较轻的患者中也有发现,这些患者被归类为患有丹特2型疾病。丹特2型疾病和洛氏综合征患者存在表型连续性,这表明在补偿酶功能丧失的能力方面存在个体差异。研究人员已经开展了大量工作来了解该疾病的病因。然而,导致临床表现的机制仍知之甚少,我们距离有效的治疗方法还很遥远。在这篇综述中,我们纳入了关于洛氏综合征和丹特2型疾病的既定研究结果和最新进展。

相似文献

2
The oculocerebrorenal syndrome of Lowe: an update.洛氏眼脑肾综合征:最新进展。
Pediatr Nephrol. 2016 Dec;31(12):2201-2212. doi: 10.1007/s00467-016-3343-3. Epub 2016 Mar 24.
7
The 5-phosphatase OCRL in Lowe syndrome and Dent disease 2.低磷酸酯酶症和 Dent 病 2 中的 5-磷酸酶 OCRL
Nat Rev Nephrol. 2017 Aug;13(8):455-470. doi: 10.1038/nrneph.2017.83. Epub 2017 Jul 3.

引用本文的文献

10
The oculocerebrorenal syndrome of Lowe: an update.洛氏眼脑肾综合征:最新进展。
Pediatr Nephrol. 2016 Dec;31(12):2201-2212. doi: 10.1007/s00467-016-3343-3. Epub 2016 Mar 24.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验